Steward Financial Group’s Intellia Therapeutics NTLA Stock Holding History

Steward Financial Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$0	Buy	+7	New	+$272	﹤0.01%	1482

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Steward Financial Group's NTLA Position: Q3 2023 in Review

Steward Financial Group opened a new position in Intellia Therapeutics (NTLA) in Q3 2023: 7 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1482 among its holdings.

284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Steward Financial Group held 7 shares of Intellia Therapeutics worth $0 as of Q3 2023.
Intellia Therapeutics was a new Steward Financial Group position in Q3 2023.
Intellia Therapeutics made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1482 holding.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.